Patient-derived xenograft (PDX) models have become an important asset in translational cancer research. However, to provide a robust preclinical platform, PDXs need to accommodate the tumor heterogeneity that is observed in patients. Colorectal cancer (CRC) can be stratified into four consensus molecular subtypes (CMS) with distinct biological and clinical features. Surprisingly, using a set of CRC patients, we revealed the partial representation of tumor heterogeneity in PDX models. The epithelial subtypes, the largest subgroups of CRC subtype, were very ineffective in establishing PDXs, indicating the need for further optimization to develop an effective personalized therapeutic approach to CRC. Moreover, we showed that tumor cell proliferation was associated with successful PDX establishment and able to distinguish patient with poor clinical outcomes within CMS2 group. This article is protected by copyright. All rights reserved.
Prasetyanti, P.R., van Hooff, S.R., van Herwaarden, T., de Vries, N., Kalloe, K., Rodermond, H., et al. (2018). Capturing Colorectal Cancer Inter-Tumor Heterogeneity in Patient-Derived Xenograft (PDX) Models. INTERNATIONAL JOURNAL OF CANCER(144), 366-371 [10.1002/ijc.31767].
Capturing Colorectal Cancer Inter-Tumor Heterogeneity in Patient-Derived Xenograft (PDX) Models
Todaro, Matilde;Stassi, Giorgio;
2018-01-01
Abstract
Patient-derived xenograft (PDX) models have become an important asset in translational cancer research. However, to provide a robust preclinical platform, PDXs need to accommodate the tumor heterogeneity that is observed in patients. Colorectal cancer (CRC) can be stratified into four consensus molecular subtypes (CMS) with distinct biological and clinical features. Surprisingly, using a set of CRC patients, we revealed the partial representation of tumor heterogeneity in PDX models. The epithelial subtypes, the largest subgroups of CRC subtype, were very ineffective in establishing PDXs, indicating the need for further optimization to develop an effective personalized therapeutic approach to CRC. Moreover, we showed that tumor cell proliferation was associated with successful PDX establishment and able to distinguish patient with poor clinical outcomes within CMS2 group. This article is protected by copyright. All rights reserved.File | Dimensione | Formato | |
---|---|---|---|
IJC-144-366.pdf
accesso aperto
Descrizione: articolo principale
Tipologia:
Versione Editoriale
Dimensione
651.91 kB
Formato
Adobe PDF
|
651.91 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.